{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:55:32Z","timestamp":1782896132182,"version":"3.54.5"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,7]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n To investigate temporal trends in treatment patterns and prognostic factors for overall survival in patients with metastatic biliary tract cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n From the Tokushukai REAl-world Data project, we identified 945 patients with metastatic biliary tract cancer treated with gemcitabine, tegafur\/gimeracil\/oteracil, gemcitabine plus cisplatin, gemcitabine plus tegafur\/gimeracil\/oteracil or gemcitabine plus cisplatin and tegafur\/gimeracil\/oteracil between April 2010 and March 2022. Stratified\/conventional Cox regression analyses were conducted to examine the association between overall survival and patient- and tumour-related factors, study period, hospital volume, hospital type and first-line chemotherapy regimen. Using inverse probability of treatment weighting with propensity scores, overall survival was also compared between monotherapy and combination therapy groups.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We enrolled 366 patients (199 men; median age, 72\u00a0years). Over a median follow-up of 5.2\u00a0months, the median overall survival was 7.0\u00a0months (95% confidence interval 6.2\u20139.0), and the median time to treatment failure was 3.5\u00a0months (95% confidence interval 3.1\u20134.5). Median overall survival and time to treatment failure for gemcitabine\/tegafur\u2013gimeracil\u2013oteracil\/gemcitabine plus cisplatin\/gemcitabine plus tegafur\u2013gimeracil\u2013oteracil\/gemcitabine plus cisplatin and tegafur\u2013gimeracil\u2013oteracil regimen were 6.2\/6.6\/7.9\/16.2\/15.1 and 2.8\/3.4\/4.1\/15.3\/7.4\u00a0months, respectively. Primary disease site, previous surgery, previous endoscopic procedures and hospital type were identified as significant prognostic factors. Inverse probability of treatment weighting analysis demonstrated that combination therapy had a significantly better prognosis than monotherapy (hazard ratio 0.61, 95% confidence interval 0.43\u20130.88, P\u00a0=\u00a00.006).<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our real-world data analysis showed that standard care for metastatic biliary tract cancer is widely used in hospitals throughout Japan and verified the survival benefits of combination therapy over monotherapy observed in prior clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Clinical trial number<\/jats:title>\n UMIN000050590 (http:\/\/www.umin.ac.jp\/ctr\/index.htm).<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jjco\/hyad133","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T17:18:42Z","timestamp":1696612722000},"page":"70-80","source":"Crossref","is-referenced-by-count":3,"title":["Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04)"],"prefix":"10.1093","volume":"54","author":[{"given":"Rai","family":"Shimoyama","sequence":"first","affiliation":[{"name":"Shonankamakura General Hospital Department of General Surgery, , Kamakura , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Imamura","sequence":"additional","affiliation":[{"name":"Kobe University Graduate School of Medicine Department of Medical Oncology and Hematology, , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Uryu","sequence":"additional","affiliation":[{"name":"Yao Tokushukai General Hospital Department of Medicine and Oncology, , Yao , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mase","sequence":"additional","affiliation":[{"name":"Ogaki Tokushukai Hospital Department of Breast Surgery, , Ogaki , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Taguri","sequence":"additional","affiliation":[{"name":"Tokyo Medical University Department of Health Data Science, , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahisa","family":"Okuda","sequence":"additional","affiliation":[{"name":"Tokyo Medical University Department of Health Data Science, , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Tokushukai Information System Inc. , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Mirai Iryo Research Center Inc. , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satomi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Mirai Iryo Research Center Inc. , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Sawamukai","sequence":"additional","affiliation":[{"name":"Mirai Iryo Research Center Inc. , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[{"name":"Kobe University Graduate School of Medicine Department of Medical Oncology and Hematology, , Kobe , Japan"},{"name":"Kobe University Hospital Cancer Center Kobe, , Kobe , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"key":"2024010813091285500_ref1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024010813091285500_ref2","volume-title":"SEER 5-year relative survival rate, 2012\u20132018","author":"Cancer Statistics Explorer Network, National Cancer Institute, United States"},{"key":"2024010813091285500_ref3","volume-title":"Cancer statistics in Japan","author":"Cancer Information Service, National Cancer Center, Japan"},{"key":"2024010813091285500_ref4","volume-title":"Annual report of hospital-based cancer registries","author":"Cancer Information Service, National Cancer Center, Japan"},{"issue":"23","key":"2024010813091285500_ref5","first-page":"149","article-title":"Biliary tract cancer registry in Japan from 2008 to 2013","volume":"2016","author":"Ishihara","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2024010813091285500_ref6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann Oncol"},{"key":"2024010813091285500_ref7","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1200\/JCO.2001.19.20.4089","article-title":"Treatment of inoperable and\/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study","volume":"19","author":"Gebbia","year":"2001","journal-title":"J Clin Oncol"},{"key":"2024010813091285500_ref8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/sj.bjc.6602208","article-title":"Phase II study of S-1 in patients with advanced biliary tract cancer","volume":"91","author":"Ueno","year":"2004","journal-title":"Br J Cancer"},{"key":"2024010813091285500_ref9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-005-0095-3","article-title":"Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer","volume":"57","author":"Okusaka","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024010813091285500_ref10","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"Sharma","year":"2010","journal-title":"J Clin Oncol"},{"key":"2024010813091285500_ref11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"2024010813091285500_ref12","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br J Cancer"},{"key":"2024010813091285500_ref13","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann Oncol"},{"key":"2024010813091285500_ref14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2024010813091285500_ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024010813091285500_ref16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024010813091285500_ref17","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evidence"},{"key":"2024010813091285500_ref18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations","volume":"3","author":"Averitt","year":"2020","journal-title":"NPJ Digit Med"},{"key":"2024010813091285500_ref19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.29245\/2572-9411\/2016\/3.1054","article-title":"Design and analysis of clinical trials for small rare disease populations","volume":"1","author":"Hilgers","year":"2016","journal-title":"J Rare Dis Res Treat"},{"key":"2024010813091285500_ref20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0272989X12472398","article-title":"Survival analysis for economic evaluations alongside clinical trials\u2014extrapolation with patient-level data: inconsistencies, limitations, a practice guide","volume":"33","author":"Latimer","year":"2013","journal-title":"Med Decis Making"},{"key":"2024010813091285500_ref21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jama.2018.10136","article-title":"Real-word evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"JAMA"},{"key":"2024010813091285500_ref22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/JMDH.S160029","article-title":"Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making","volume":"11","author":"Katkade","year":"2018","journal-title":"J Multidiscip Healthc"},{"key":"2024010813091285500_ref23","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jval.2017.03.008","article-title":"On behalf of GetReal work package 1. What is real-world data? A review of definitions based on literature and stakeholder interviews","volume":"20","author":"Makady","year":"2017","journal-title":"Value Health"},{"key":"2024010813091285500_ref24","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.3390\/healthcare10112146","article-title":"Real-world outcome of systemic therapy in Japanese patients with cancer (Tokushkai REAl-world data project: TREAD): study protocol for nationwide cohort study","volume":"10","author":"Shimoyama","year":"2022","journal-title":"Healthcare (Basel)"},{"key":"2024010813091285500_ref25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/jjco\/hyac034","article-title":"Overview of the ethical guidelines for medical and biological research involving human subjects in Japan","volume":"52","author":"Eba","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2024010813091285500_ref26","author":"Cancer Information Service, National Cancer Center, Japan"},{"key":"2024010813091285500_ref27","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2024010813091285500_ref28","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2024010813091285500_ref29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"2024010813091285500_ref30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jhbp.233","article-title":"Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition","volume":"22","author":"Miyazaki","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2024010813091285500_ref31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00280-009-1115-5","article-title":"Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer","volume":"65","author":"Sasaki","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024010813091285500_ref32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00280-014-2648-9","article-title":"A multi-institution phase II study of gemcitabine\/cisplatin\/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002)","volume":"75","author":"Kanai","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2024010813091285500_ref33","doi-asserted-by":"crossref","first-page":"VIII205","DOI":"10.1093\/annonc\/mdy282","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA)","volume":"29","author":"Sakai","year":"2018","journal-title":"Ann Oncol"},{"key":"2024010813091285500_ref34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jhbp.870","article-title":"Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition","volume":"28","author":"Nagino","year":"2021","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2024010813091285500_ref35","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s10637-021-01098-2","article-title":"Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer","volume":"39","author":"Inoue","year":"2021","journal-title":"Invest New Drugs"},{"key":"2024010813091285500_ref36","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3892\/or.2023.8478","article-title":"Clinical outcomes of second line chemotherapy after gemcitabine and cisplatin plus S 1 treatment for patients with advanced biliary tract cancer in the KHBO1401 3A study","volume":"49","author":"Shindo","year":"2023","journal-title":"Oncol Rep"},{"key":"2024010813091285500_ref37","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"2024010813091285500_ref38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2020.05.014","article-title":"Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer","volume":"73","author":"McNamara","year":"2020","journal-title":"J Hepatol"},{"key":"2024010813091285500_ref39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/jjco\/hyu059","article-title":"Current status of medical oncology in Japan\u2014reality gleaned from a questionnaire sent to designated cancer care hospitals","volume":"44","author":"Takiguchi","year":"2014","journal-title":"Jpn J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/1\/70\/55123976\/hyad133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/1\/70\/55123976\/hyad133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T13:41:13Z","timestamp":1704721273000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/1\/70\/7292043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,5]]},"published-print":{"date-parts":[[2024,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad133","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,10,5]]}}}